Search PubMed⌕ Search

Biomedical subjects

G Kanra

Publications and source records attributed to G Kanra.

18 recordsLinked to original sources
PubMed1992

Complement component deficiencies and infection: C5, C8 and C3 deficiencies in three families.

Three families are described with complement component deficiencies. In one family, five children had C5 deficiency; in a second family, two children had C8 deficiency and one child in a third family had C3 deficiency. The index cases were identified during screening of patients with recurrent pyogenic infections, recurrent meningitis and meningococcaemia. Two of the five C5 deficient patients had recurrent meningitis and meningococcaemia, two had recurrent respiratory tract infections and otitis and one was healthy. One of the C8 deficient patients had meningitis, meningococcaemia and pneumonia, whereas his sibling with the same deficiency was healthy. The patient with C3 deficiency had four episodes of meningitis and recurrent otitis.

Child↗
PubMed1992

[Fatal varicella pneumonia unresponsive to acyclovir therapy in a child with a malignancy].

Acyclovir has become the drug of choice for prevention of visceral dissemination of Varicella-zoster virus infections in immunocompromised individuals. This article describes a 6-year-old girl taking cytotoxic therapy and radiotherapy for treatment of Hodgkin lymphoma who developed cutaneous varicella infection. Despite the early administration of acyclovir a fatal varicella pneumonia occurred and she died on the 4th day of hospitalization. Since the resistance is inducible, the increase of unresponsiveness to acyclovir in immunocompromised hosts with varicella infection is a potential risk that can cause to increase in fatalities in these patients.

Acyclovir↗
PubMed1991

Two trials of an acellular DTP vaccine in comparison with a whole-cell DTP vaccine in infants: evaluation of two PT doses and two vaccination schedules.

The present trials being carried out in Switzerland and Turkey, the reactogenicity and immunogenicity of acellular DTP vaccines containing either 25 micrograms or 8 micrograms of PT and 25 micrograms of FHA were compared with those of a conventional whole-cell DTP vaccine during a primary vaccination course following either a 0-1-2 schedule starting at three months of age (Switzerland) or a 0-2-4 schedule starting at two months of age (Turkey). The whole-cell vaccine was associated with significantly more local reactions than the acellular vaccines; general reactions were also more frequent among whole-cell recipients. The 25 micrograms PT dose vaccine was no more reactogenic than the 8 micrograms PT dose vaccine. There was no evidence of increases in frequencies of local or general reactions from one acellular vaccine dose to the next. The 25 micrograms PT dose acellular DTP vaccine resulted in immune responses to all four antigens (PT, FHA, diphtheria and tetanus toxoids) at least equivalent to those observed with whole-cell vaccination. Significantly lower anti-PT antibody levels were seen with the 8 micrograms PT dose vaccine.

Antibodies, Bacterial↗
PubMed1978

Thrombocytopenic purpura related to rubella infection.

Serologic studies for rubella (hemagglutination inhibition and complement fixation changes) were carried out at two-week intervals in 15 patients with acute idiopathic thrombocytopenic purpura and in age-matched controls in the same season during a small rubella epidemic. Hemagglutination inhibition, sucrose density gradient for hemagglutination inhibition, and complement fixation titer changes implicated recent rubella infection as an etiologic factor in five of the 15 patients.

Adolescent↗
PubMedDate not supplied

The evaluation of vaccination against measles at nine months of age (report of an epidemic).

Sixteen measles cases were studied during an epidemic that broke out in Etimesgut district of Ankara. Eight of these children had never been vaccinated against measles while the remainder had been vaccinated at nine months of age. In the sera obtained during the course of the illness, anti-measles antibody was not detectable in six vaccinated children and in four unvaccinated children. Upon observing the siblings of the subjects, it was determined that one out of three who had not been vaccinated against measles and three out of seven who had been vaccinated at nine months of age contracted the disease within a month. However none of the siblings who had been vaccinated against measles at 15 months contracted the disease. In our cases, although vaccination at nine months of age could not prevent measles, it resulted in a milder form of the disease. It seems that measles vaccine administered to infants at around nine months of age does not prevent the occurrence of the disease in many children.

Age Factors↗
PubMedDate not supplied

Elimination of maternal antibodies against measles (is the policy of vaccinating children younger than nine months of age suitable for Turkey?).

Maternal antibodies against measles in 223 healthy children aged 22 to 31 weeks were studied. The ratio of children with detectable antibodies declined from 61.4 percent at 22-23 weeks of age to 20 percent at 26-27 weeks of age. Since the minimum proportion of antibody-positive children (15.6% at 26-27 weeks of age) is still higher than the optimum proportion (5%), the Schwarz vaccine which is used mostly in measles immunization seems not to be effective to obtain a high seroconversion rate in our infants. We suggest that the Edmonston-Zagreb strain of measles vaccine be used for infants under 9 months of age in Turkey.

Age Factors↗
PubMedDate not supplied

Serological evaluation of 52 children immunized with the combined measles, mumps and rubella vaccine.

Fifty-two of 298 children vaccinated with the measles-mumps-rubella (MMR) vaccine at around the age of 16 months were evaluated for antibody titres against measles, mumps, and rubella. The seropositivity rates for measles, mumps, and rubella were 86%, 92%, and 98%, respectively. While the most prominent side effects were irritability (6.04%) and fever (4.69%), 83.55% of the vaccinated children showed no undesirable reaction to the vaccine. The MMR vaccine appeared to be immunogenic and nonreactogenic for the children in the study.

Antibodies, Viral↗